Scutellarein
Based on 14 publication(s) in Google Scholar
Scutellarein is a natural flavonoid compound with anti-inflammatory effects.
Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.
- Reinheit: 99.39%
- CAS. Nr.: 529-53-3
- Formel: C15H10O6
- Molecular Weight:286.24
-
Speicherung:
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications Citing Use of MedChemExpress (MCE) Scutellarein
More- Nucleic Acids Res. 2021 Jan 8;49(D1):D1113-D1121. [Abstract]
- Acta Pharm Sin B. 2021 Jan;11(1):143-155. [Abstract]
- Cell Chem Biol. 2022 Jul 21;29(7):1113-1125.e6. [Abstract]
- Int J Mol Med. 2023 Jul;52(1):55. [Abstract]
- Phytother Res. 2026 May;40(5):2986-3008. [Abstract]
- Biochem Pharmacol. 2025 Apr 4:116932. [Abstract]
- Food Front. 2026 May 28;7(4):e70301.
- Pharmaceuticals (Basel). 2026 Feb 12;19(2):307. [Abstract]
- Pharmaceuticals (Basel). 2022 Jan 31;15(2):179. [Abstract]
- Mol Med Rep. 2024 May;29(5):84. [Abstract]
- J Immunol. 2022 Feb 1;208(3):753-761. [Abstract]
- Vet Microbiol. 2026 May:316:110992. [Abstract]
- Medicine (Baltimore). 2025 Sep 26;104(39):e44506. [Abstract]
- Andrologia. 2022 Dec;54(11):e14625. [Abstract]
-
Cell Proliferation/Viability Assay
-
In Vivo Efficacy Study
-
Histological Imaging/Staining
-
WB
-
Others
Biologische Aktivität
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| HEK293 | EC50 |
16.4 μM
Compound: 11
|
Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay
Agonist activity at mouse PPARgamma expressed in HEK293 cells co-expressing with Gal4 reporter vector after 24 hrs by dual-luciferase reporter assay
|
[PMID: 24955889] |
| MV4-11 | IC50 |
27.07 μM
Compound: 23
|
Antiproliferation activity against human MV4-11 cells assessed as reduction in cell viability measured by Cell-titer-Glo assay
Antiproliferation activity against human MV4-11 cells assessed as reduction in cell viability measured by Cell-titer-Glo assay
|
[PMID: 32088124] |
| RBL-2H3 | IC50 |
67.2 μM
Compound: 3
|
Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
Antihistaminic activity in rat RBL2H3 cells assessed as inhibition of DNP-BSA-induced beta-hexosaminidase release preincubated for 10 mins before DNP-BSA challenge
|
[PMID: 14510616] |
Scutellarein (0-200 μM, 24 h) inhibits NO production, reduces the mRNA expression levels of iNOS and TNF-α in LPS-activated RAW264.7 cells[1].
Scutellarein (0-50 μM, 24 h) inhibits proliferation, migration, colony formation and induces the apoptosis of HT1080 cells[3].
Scutellarein (0-50 μM, 24 h) inhibits MMP-2, -9 and -14 expression and NF-κB activation in HT1080 cells[3].
Scutellarein shows DPPH, ABTS+·, ·OH radical-scavenging activity (IC50: 16.84 μM, 3.00 μM, 0.31 mM respectively)[4].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Scutellarein (50 and 500 mg/kg) inhibits tumor growth in a mouse HT108 xenograft model[3].
Scutellarein (0-1.40 mmol/kg, p.o.) improves neuronal injury, and protects rats from cerebral ischemia[5].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:HFD mice[2]
-
Dosage:50 mg/kg
-
Administration:in diet, 16 weeks
-
Result:Reduced lipid accumulation and levels of inflammatory factors in the liver.
Reduced the Body Weight.
Chemical Information
-
CAS. Nr. 529-53-3
-
Appearance Solid
-
Molecular Weight 286.24
-
Formel C15H10O6
-
Color Light yellow to yellow
-
SMILES
O=C1C=C(C2=CC=C(O)C=C2)OC3=CC(O)=C(O)C(O)=C13
-
Synonyms
6-Hydroxyapigenin; 4',5,6,7-Tetrahydroxyflavone
-
Structure Classification
-
Initial Source
-
Versand
Room temperature in continental US; may vary elsewhere.
-
Speicherung
4°C, protect from light
* In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
Publications (14)
-
Journal Impact Factor
-
Most Recent
-
Nucleic Acids Res
COVID19 Drug Repository: text-mining the literature in search of putative COVID19 therapeutics. [Abstract]2021 Jan 8;49(D1):D1113-D1121. PMID: 33166390 -
Acta Pharm Sin B
Chrysin serves as a novel inhibitor of DGK α/FAK interaction to suppress the malignancy of esophageal squamous cell carcinoma (ESCC). [Abstract]2021 Jan;11(1):143-155. PMID: 33532186 -
Cell Chem Biol
Identifying enhancers of innate immune signaling as broad-spectrum antivirals active against emerging viruses. [Abstract]2022 Jul 21;29(7):1113-1125.e6. PMID: 35728599 -
Int J Mol Med
Scutellarein regulates the PTEN/AKT/NFκB signaling pathway to reduce pirarubicin related liver inflammation. [Abstract]2023 Jul;52(1):55. PMID: 37232353
Scutellarein purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2023 Jul;52(1):55. [Abstract]
Effects of THP and Sc (Scutellarein: 100 mg/kg) on body weight in rats over 6 weeks.
Scutellarein purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2023 Jul;52(1):55. [Abstract]
Effects of THP and Sc (Scutellarein: 100 mg/kg) on the morphology of rat liver tissue.
Scutellarein purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2023 Jul;52(1):55. [Abstract]
Effects of THP and Sc (Scutellarein: 100 mg/kg) on the expression of p65, AKT, PTEN and IκBα proteins in rat liver.
Scutellarein purchased from MedChemExpress. Usage Cited in: Int J Mol Med. 2023 Jul;52(1):55. [Abstract]
The optimal concentration of Sc (Scutellarein) for treating hepatocytes was screened under a treatment condition of 5 µmol/L THP.
-
Phytother Res
Scutellarein Attenuates Intervertebral Disc Degeneration by Promoting PINK1/Parkin-Mediated Mitophagy to Alleviate Inflammation, Ferroptosis, and Mitochondrial Dysfunction in Nucleus Pulposus Cells. [Abstract]2026 May;40(5):2986-3008. PMID: 41815012 -
Biochem Pharmacol
Scutellarein ameliorates pulmonary arterial hypertension via sirtuin 1 mediated deacetylation of nicotinamide nucleotide transhydrogenase. [Abstract]2025 Apr 4:116932. PMID: 40189160 -
-
Pharmaceuticals (Basel)
Discovery of Plant-Derived Natural Compounds as Novel GABA Aminotransferase Inhibitors: Structure-Based Discovery, Experimental Validation, and Molecular Dynamics Analysis. [Abstract]2026 Feb 12;19(2):307. PMID: 41754847
Scutellarein purchased from MedChemExpress. Usage Cited in: Pharmaceuticals (Basel). 2026 Feb 12;19(2):307. [Abstract]
ell-based inhibitory effects of plant-derived aglycones on GABA-AT activity in HepG2 cells. Cells were treated with quercetin, salvianolic acid A, scutellarein, or vigabatrin at the indicated concentration (1, 10, 100 μM) for 2 days, followed by cell lysis. Intracellular GABA-AT activity was quantified using a resazurin-based coupled assay.
-
Pharmaceuticals (Basel)
Bruceine D Identified as a Drug Candidate against Breast Cancer by a Novel Drug Selection Pipeline and Cell Viability Assay. [Abstract]2022 Jan 31;15(2):179. PMID: 35215292 -
Mol Med Rep
Food therapy of scutellarein ameliorates pirarubicin‑induced cardiotoxicity in rats by inhibiting apoptosis and ferroptosis through regulation of NOX2‑induced oxidative stress. [Abstract]2024 May;29(5):84. PMID: 38516760 -
J Immunol
SARS-CoV-2 NSP13 Inhibits Type I IFN Production by Degradation of TBK1 via p62-Dependent Selective Autophagy. [Abstract]2022 Feb 1;208(3):753-761. PMID: 34996837 -
Vet Microbiol
The Chinese medicine monomer Schisandrin C inhibits PRRSV infection by regulating the OGT-PI3K/AKT/mTOR signaling pathway. [Abstract]2026 May:316:110992. PMID: 41865607 -
Medicine (Baltimore)
Scutellarein attenuates alcohol-induced hepatocyte injury by modulating NF-κB and NRF2 signaling pathways. [Abstract]2025 Sep 26;104(39):e44506. PMID: 41029150 -
Andrologia
Scutellarein stimulates human sperm function by increasing the levels of intracellular calcium and tyrosine phosphorylation. [Abstract]2022 Dec;54(11):e14625. PMID: 36257765
Lösungsmittel & Löslichkeit
DMSO : ≥ 30 mg/mL (104.81 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)
* "≥" means soluble, but saturation unknown.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
Konzentration (Stammlösung) × Volumen (Stammlösung) = Konzentration (Ziellösung) × Volumen (Ziellösung)
Select the appropriate dissolution method based on your experimental animal and administration route.
- For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
- To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
- The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (7.27 mM); Clear solution
This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Please enter the basic information of animal experiments:
-
-
-
-
Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
Please enter your animal formula composition:
-
%DMSO +
Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
-
%+
-
+%Tween-80 + +
-
%Saline +
The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
Working solution concentration: 0.22 mg/mL
Method for preparing stock solution: mg drug dissolved in μL DMSO. Stock solution concentration: mg/mL. * In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)
1. Take μL DMSO stock solution;
2. Add μL .
μL , mix evenly;
3. Then add μL Tween 80, mix evenly;
4. Then add μL
Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
Reinheit & Dokumentation
-
Data Sheet (276 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Handling Instructions (2659 KB)
Verweise
[2]. Lin Y, et al. Novel anti-obesity effect of scutellarein and potential underlying mechanism of actions. Biomed Pharmacother. 2019 Sep;117:109042. [Content Brief]
[3]. Shi X, et al. Scutellarein inhibits cancer cell metastasis in vitro and attenuates the development of fibrosarcoma in vivo. Int J Mol Med. 2015 Jan;35(1):31-8. [Content Brief]
[4]. Qian LH, et al. Synthesis and bio-activity evaluation of scutellarein as a potent agent for the therapy of ischemic cerebrovascular disease. Int J Mol Sci. 2011;12(11):8208-16. [Content Brief]
[5]. Tang H, et al. Neuroprotective effects of scutellarin and scutellarein on repeatedly cerebral ischemia-reperfusion in rats. Pharmacol Biochem Behav. 2014 Mar;118:51-9. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| DMSO | 1 mM | 3.4936 mL | 17.4679 mL | 34.9357 mL | 87.3393 mL |
| 5 mM | 0.6987 mL | 3.4936 mL | 6.9871 mL | 17.4679 mL | |
| 10 mM | 0.3494 mL | 1.7468 mL | 3.4936 mL | 8.7339 mL | |
| 15 mM | 0.2329 mL | 1.1645 mL | 2.3290 mL | 5.8226 mL | |
| 20 mM | 0.1747 mL | 0.8734 mL | 1.7468 mL | 4.3670 mL | |
| 25 mM | 0.1397 mL | 0.6987 mL | 1.3974 mL | 3.4936 mL | |
| 30 mM | 0.1165 mL | 0.5823 mL | 1.1645 mL | 2.9113 mL | |
| 40 mM | 0.0873 mL | 0.4367 mL | 0.8734 mL | 2.1835 mL | |
| 50 mM | 0.0699 mL | 0.3494 mL | 0.6987 mL | 1.7468 mL | |
| 60 mM | 0.0582 mL | 0.2911 mL | 0.5823 mL | 1.4557 mL | |
| 80 mM | 0.0437 mL | 0.2183 mL | 0.4367 mL | 1.0917 mL | |
| 100 mM | 0.0349 mL | 0.1747 mL | 0.3494 mL | 0.8734 mL |